| HIV/AIDS researchers called for an increase
in basic research on the virus and new strategies for research into a
vaccine on Tuesday during an NIH AIDS Vaccine Summit, the New York Times
reports. The summit was held to discuss the future of HIV vaccine research
following the recent failure of a Merck vaccine candidate (Altman, New York
Times, 3/26). Merck in September 2007 announced it had halted a large-scale
clinical trial of its experimental HIV vaccine after the drug failed to
prevent HIV infection in participants or prove effective in delaying the
progression of the virus to AIDS. The vaccine candidate also might have put
some trial participants at an increased risk of HIV (Kaiser Daily HIV/AIDS
Report, 3/25).Experts at the meeting said that NIH's National Institute of
Allergy and Infectious Diseases should support basic research into HIV
prevention, testing and treatment strategies. In addition, researchers said
NIAID should support efforts to develop animal models of HIV, and they also
called for cooperation between scientists developing such models and those
developing vaccine candidates (New York Times, 3/26). NIAID Director Anthony
Fauci at the meeting said scientists should begin to focus research on
discoveries about the immune system, animal models and innovative vaccine
concepts (Chase, Wall Street Journal, 3/26). According to Fauci, more
fundamental knowledge about HIV, as well as the way the body and
experimental vaccines respond to the virus, is needed before a safe and
effective vaccine can be developed (New York Times, 3/26). "We need to turn
the knob toward [basic scientific] discovery -- nobody should be unclear
about that," he said. Carl Dieffenbach, head of NIH's Division of AIDS, said
that the "summit does mark a change in our approach. "Several researchers at
the meeting -- which drew about 300 scientists from around the world -- said
NIAID should fund new, innovative research proposals and support younger
scientists who might abandon HIV vaccine research for less challenging
fields (Brown, Washington Post, 3/26). Fauci said an initial step would be
to trim existing projects to provide $10 million to $15 million in immediate
funds for about 30 grants for researchers who propose novel ideas. He added
that some of the grants would go to young scientists (New York Times, 3/26).
According to the Post, NIH is spending about $497 million
on HIV vaccine research this year, with about $476 million going to
researchers not affiliated with the agency. About 47% of the funds go toward
basic research, while 38% go toward human testing of vaccine candidates
(Washington Post, 3/26). Fauci said that he will try to increase funding for
vaccine research (Emery, Baltimore Sun, 3/26).
Reaction
Fauci said that there is not an "immediate solution to the
problem," adding that researchers will need to "justify what [they] are
doing" and determine the next steps during smaller meetings (New York Times,
3/26). Michael Weinstein, president of the AIDS Healthcare Foundation,
called on researchers to "pull the plug on vaccine research," adding, "Do we
have any other enterprise that has been studied for 25 years and for which
we've spent billions of dollars where we have no results?" He added that
there is "no evidence we'll ever have an AIDS vaccine." Mitchell Warren of
the AIDS Vaccine Advocacy Coalition in response to Weinstein said that the
failure of the Merck trial "is not the end of the line for AIDS vaccine
research," adding that it is a "critical moment in the field" (Washington
Post, 3/26). Glenda Gray of the University of Witwatersrand in South Africa
added that "any call to halt vaccine funding is like abandoning Africa."
Fauci responded that "under no circumstances" would researchers "discontinue
AIDS vaccine research" (Wall Street Journal, 3/26). "We will not discontinue
research, period," Fauci said, adding, "Not only will we not decrease it, we
will in fact try to increase it" (Baltimore Sun, 3/26).
Access this story and related links online:
http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=51151 |